Suzhou Xinqing Medical Technology Co., Ltd., founded in 2017 by Dr. Xu Bozhen, focuses on the development of in-vitro artificial heart devices aimed at assisting patients with cardiovascular illnesses. The company specializes in creating short-term to medium-term ventricular assist devices that leverage advanced fluid mechanics and magnetic suspension technology. These innovations allow the devices to be compatible with various blood types, thereby reducing the risk of incompatibility for patients. With a team of leading experts in artificial heart engineering, the company has successfully developed an artificial heart that holds independent intellectual property rights, positioning itself as a key player in the medical technology sector.
Aldatu Biosciences Inc. specializes in diagnostics for detecting drug resistance in antiretroviral treatments for HIV. The company utilizes its proprietary PANDAA technology, developed at Harvard University, to provide a robust solution for HIV genotyping. This platform enables healthcare providers to match patients with appropriate drugs, ultimately enhancing patient outcomes and reducing the overall costs associated with HIV care. Founded in 2014 and based in Cambridge, Massachusetts, Aldatu Biosciences is committed to advancing global health through innovative diagnostic solutions that address both infectious diseases and emerging health challenges. As a Public Benefit Corporation, the company focuses on improving patient care and healthcare cost efficiency worldwide.
Noninvasix, Inc. is a medical technology company based in Galveston, Texas, that specializes in non-invasive precision oximetry for measuring brain oxygenation in preterm infants within neonatal intensive care units. Founded in 2007 by Dr. Donald Prough and Dr. Rinat Esenaliev at the University of Texas Medical Branch, the company has developed a novel optoacoustic platform technology that allows for continuous monitoring of oxygen sufficiency in organs and veins without the need for invasive procedures. This technology is particularly useful in diagnosing and managing conditions such as sepsis and septic shock, enabling clinicians to assess tissue hypoxia in real-time and adjust treatments accordingly. Noninvasix has received over $6.8 million in funding, including substantial grants from the NIH and DOD, and has been recognized in various prestigious accelerator programs. The company's innovations have been validated in multiple peer-reviewed studies, and its intellectual property includes numerous patents both in the U.S. and internationally.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.